SCHEMBL17237172

SCHEMBL17237172

COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1N/C=C\C(=O)c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 6/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ ATM Q13315 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ CXCL12 P48061 1/20 0.56
▸ TUBB1 Q9H4B7 3/20 0.54
▸ TUBB4A P04350 2/20 0.54
▸ TUBB P07437 2/20 0.54
▸ TUBA3C P0DPH7 2/20 0.54
▸ TUBA1B P68363 2/20 0.54
▸ TUBA4A P68366 2/20 0.54
▸ TUBB4B P68371 2/20 0.54
▸ TUBB3 Q13509 2/20 0.54
▸ TUBB2A Q13885 2/20 0.54
▸ TUBB8 Q3ZCM7 2/20 0.54
▸ TUBA3E Q6PEY2 2/20 0.54
▸ TUBA1A Q71U36 2/20 0.54
▸ TUBA1C Q9BQE3 2/20 0.54
▸ TUBB6 Q9BUF5 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17237175 1.00 KRAS (0.67) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237111 0.92 KRAS (0.72) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237114 0.92 KRAS (0.72) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237301 0.91 TUBB1 (0.60) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237303 0.91 TUBB1 (0.60) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17244223 0.90 KRAS (0.67) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237394 0.90 BACE1 (0.56) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17251595 0.90 CA1 (0.67) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17237391 0.90 BACE1 (0.56) KRASALDH1A1ATMSMN1; SMN2L3MBTL1
SCHEMBL17236830 0.90 ABCG2 (0.60) KRASTUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP claimed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US claimed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US claimed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP claimed
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP disclosed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS MCL1, HCCS, CASP3 KRAS 528/4885ALDH1A1 119/4885ATM 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback